BioTuesdays

Tag - PNT

Point Biopharma

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...